Who are bupropion + nicotine gum's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupropion-nicotine-gum.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

bupropion + nicotine gum — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bupropion + nicotine gum (bupropion + nicotine gum) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination smoking cessation therapy (antidepressant + nicotine replacement). Area: Addiction Medicine / Smoking Cessation.

marketed Combination smoking cessation therapy (antidepressant + nicotine replacement) Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine) Addiction Medicine / Smoking Cessation Small molecule Live · refreshed every 30 min

Target snapshot

bupropion + nicotine gum (bupropion + nicotine gum) — University of Wisconsin, Madison. Bupropion inhibits norepinephrine and dopamine reuptake to reduce cravings and withdrawal symptoms, while nicotine gum provides nicotine replacement therapy to satisfy addiction and support smoking cessation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupropion + nicotine gum TARGET	bupropion + nicotine gum	University of Wisconsin, Madison	marketed	Combination smoking cessation therapy (antidepressant + nicotine replacement)	Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination smoking cessation therapy (antidepressant + nicotine replacement) class)

University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bupropion + nicotine gum — Competitive Intelligence Brief. https://druglandscape.com/ci/bupropion-nicotine-gum. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab